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Polycystic ovary syndrome (PCOS) is an endocrine disorder in 
women. Omentin-1 and vaspin are secretary adipokines that are 
produced by the visceral adipose tissue. These levels change in 
obese women with PCOS. The aim of this study is to investigate 
whether omentin and vaspin levels change in nonobese PCOS 
subjects. This study is a cross-sectional case control study in 
which 39 women with PCOS were picked out for this study. The 
inclusion criteria were based on the Rotterdam 2003 diagnostic 
criteria. The control group consisted of 39 women with normal 
pelvic sonographic reports having regular menstruation and 
showing no signs of infertility. The fasting plasma glucose 
(FPG), triglyceride (TG), Chol, and high-density lipoprotein 
cholesterol (HDL-C), insulin, testosterone, omentin and vaspin 
were measured by the enzymatic methods. The differences 
within these groups were calculated by the un-paired t-test 
and the Mann–Whitney test. The results from this study show 
a significant increase in the amount of insulin, testosterone, 
homeostasis model assessments for insulin resistance, TG and 
lower HDL in the patient group. No significant differences were 
seen in omentin, vaspin, FPG, Cho, low-density lipoprotein, very 
low-density lipoprotein cholesterol, blood urea nitrogen, Cr 
and homeostasis model assessments for B cell function levels 
between groups. Results show that PCOS is not a determinant 
of decreased omentin and vaspin plasma levels and those high 
androgen level and insulin resistances are warning signs of 
PCOS.
Keywords: Homeostasis model assessment, insulin resistance, 
omentin-1, polycystic ovary syndrome, vaspin
Introduction
Polycystic ovary syndrome (PCOS) is the most commonly 
encountered endocrine disorder in women, affecting 5–10% of 
all women in the reproductive age [1]. PCOS is characterized by 
menstrual dysfunction and hyperandrogenism. It is associated 
with insulin resistance, pancreatic β-cell dysfunction, impaired 
glucose tolerance, type 2 diabetes, dyslipidemia and visceral 
obesity [2].
This metabolic syndrome (PCOS) is associated with an exces-
sive accumulation of central body fat. The adipose tissue plays 
a role in energy storage and also it produces several hormones 
and cytokines termed adipokines that have important role in 
the pathogenesis of insulin resistance, diabetes and atheroscle-
rosis [3].
Omentin is a newly identified secretary adipokine that 
expressed by the visceral adipose tissue relative to subcutaneous 
adipose level [4–6]. In vitro studies have shown that omentin 
increase insulin signal transduction by activating the protein 
kinase Akt/protein kinase B and by enhancing insulin-stimulated 
glucose transport in isolated human adipocytes [4]. Most studies 
published so far have shown an inverse correlation of omentin 
with obesity [7,8]. Tan et al. [7] have reported that omentin is 
decreased in patients with PCOS, the disease which is commonly 
associated with insulin resistance and obesity.
Vaspin, another insulin-sensitizing adipokin derived from 
the visceral adipose tissue, plays an important role by inhibiting 
serine phosphorilase among insulin receptor-1 (irs-1) and insulin 
receptor-2 (irs-2) [9,10].
In some published articles, a negative correlation between 
obese PCOS with omentin and a positive association with vaspin 
plasma concentration was found [7,11,12]. Mahde et al. (2009) 
confirmed that these adipokines may be used for future diagnosis 
of PCOS with obesity.
So far, only one study has published about the effect of PCOS 
on visceral hormone derived; omentin in nonobese PCOS 
patients [13]. We conducted this study to investigate that omentin 
and vaspin change in nonobese PCOS patients as well as obese 
PCOS patients. In addition, we examined the plasma concentra-
tion of lipidemic and glycemic parameters and the insulin and the 
androgen hormones.
Material and method
This study is a cross-sectional case control study. Seventy-
eight women were studied in two equal member groups (the 
treatment group and the control group). Thirty-nine women 
21.68 ± 4.01 years old with PCOS who had been referred to 
the gynecological and obstetrics Abolfazl Specialized Clinic 
were chosen for this study. Inclusion criteria were based on the 
Rotterdam 2003 diagnostic criteria. The affected woman had 
to fulfill at least two criteria out of three (little or no ovulation, 
clinical hyperandrogynism and the showing up of a polycystic 
ovary in the sonogram) [14]. The control group consisted of 
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39 women in 24.06 ± 5.07 year old range with a normal pelvis 
sonography, regular menstruation, no hysterectomy, no acne 
and no sign of infertility. Both groups matched in body mass 
index (BMI) and age.
They were excluded if they had a recent history (within 6 
months) of myocardial infarction or stroke, significant liver or 
renal disease (plasma creatinine >130 μmol/l), microproteinuria, 
thyroid disorders, neoplasm, diabetes, cushing, hyperprolac-
tonemia and hypertension. They should not have taken contra-
ceptive, glycocorticoid, ovulation stimulation, antihypertensive, 
oral hypoglycemic, weight loses, estrogen or antiandrogen medi-
cations. All patients fulfilled the following criteria: fasting plasma 
glucose (FPG) <110 mg/dl, BMI <25 kg/m2, serum triglycerides 
(TGs) <150 mg/dl and age <40 years old. The study was approved 
by the Ethics Committee of the Medical Sciences of Bushehr 
University and the reported investigations were carried out in 
accordance with the principles of the Declaration of Helsinki as 
revised in 2000. Also the participants in the project gave written 
consent.
Venous blood samples were taken between 8 a.m. and 9 a.m, 
in the follicular phase, between the first and the fourth day of 
menstruation. Plasma was obtained from the blood samples by 
adding 1 mg/ml Na2-EDTA. The blood samples were centrifuged 
at 3000 g for 15 minutes at 4°C. Immediately after centrifugation, 
the plasma samples were frozen and stored at −80°C for a period 
of no more than 6 weeks.
All measurements were carried out at the research labora-
tory of the Persian Gulf Tropical Medicine Research Center, 
Bushehr University of Medical Science. FPG was measured by 
the glucose-oxidase method of Pars Azmoon-co, Iran (intraassay 
and interassay coefficients of variation (CVs) were 3.5% and 
3.0%, respectively). The total high-density lipoprotein choles-
terol (HDL-C) levels (after precipitation with magnesium chlo-
ride) were measured by enzymatic techniques (Pars Azmoon-co, 
Iran); intraassay and interassay CVs were 1.5% and 1.9%, respec-
tively. The low-density lipoprotein cholesterol (LDL-C) level was 
calculated by using the Friedewald formula [15].
The plasma insulin (intraassay and interassay CVs 2.8% and 
3.5%, respectively), testosterone (intraassay and interassay CVs 
3.1% and 4%, respectively), vaspin (intraassay and interassay CVs 
3.8% and 4.5%, respectively) and omentin concentration (intraassay 
and interassay CVs 3.5% and 4.2%, respectively) were measured 
by enzyme-linked immunosorbant assay technique. (The insulin 
kit is the brand of DRG German Company and omentin-1 kit is 
the brand of APOTECH Company). The insulin resistance was 
estimated by homeostasis model assessments for insulin resistance 
(HOMA-IR) and β-cell dysfunction calculated by homeostasis 
model assessments for B cell function (HOMA-B).
HOMA-IR was obtained by [16]:
HOMA IR = 
Insulin IU
ml
FBS mmol
ml−








µ ×
22 5.
 HOMA-B was calculated by [17]:
HOMA B
Insulin IU
ml
FBS mmol
ml
− =
× 





 −
20
3 5
µ
.
 Weight and height was measured by using stadiometer standard 
techniques. The BMI was calculated by kg weight/m2 height.
Statistical analysis
Statistical analysis of the data was performed using SPSS statistical 
software version 11.0. All results were expressed as mean ± SD. The 
single sample Kolmogrov–Smirnov test was used to estimate the 
variables’ distribution characteristics. Unpaired t-test was used to 
compare variables with normal distribution and Mann–Whitney 
for data with nonparametric distribution. With a calculated 
sample size of 87 persons for the PCOS and for the control groups, 
the study had the power of 90.5% to yield a statistically significant 
result between these two groups. Two-tailed probability value of 
p < 0.05 was considered as statistically significant.
Results
The distribution was not normal for omentin-1, vaspin and 
insulin and normal for FPG, TG, Chol, LDL-C, HDL-C, very 
low-density lipoprotein cholesterol (VLDL), blood urea nitrogen 
(BUN), Cr, testosterone, HOMA-B and HOMA-IR. Seventy-eight 
assigned subjects completed the study. The characteristics of the 
patients confirmed and the groups were well matched for all entry 
criteria (Table I), The result from this study shows that there is 
no significant variation in the amount of omentin, vaspin, plasma 
FPG, Cho, LDL, VLDL, BUN, Cr and HOMA-B in the case and 
the control groups. There is a significant increase in amount of 
insulin (p = 0.007), testosterone (p = 0.009), HOMA-IR (p = 0.005), 
TG (p = 0.04) and lower HDL (p = 0.014) in the patient group as 
compared to the control group (Table II).
Table I. Baseline demographic characteristics of the patients (n = 78). 
Means ± SD.
Characteristic No. Control group (n = 39) Patient group (n = 39) p value
Age (years) 24.06 ± 6.58 21.68 ± 4.01 NS
Sex (n)    
Women 39 39  
Weight (kg) 57.27 ± 6.58 55.7 ± 5.59 NS
Height (cm) 161.67 ± 5.6 157.14 ± 6.08 NS
BMI (kg/m2) 21.87 ± 1.83 22.58 ± 2.14 NS
WHR 0.81 ± 0.08 0.80 ± 0.15 NS
BMI, body mass index; WHR, waist–hip ratio. NS, Not significant.
Table II. Mean (SD) concentration in variables in polycystic ovary 
syndrome and control groups.
Characteristic Control group Patient group p value
Omentin-1 (ng/ml) 26.89 ± 18.69 22.47 ± 13.31 NS
Vaspin (ng/ml) 1.13 ± 1.9 0.90 ± 1.4 NS
Insulin (µIU/ml) 13.53 ± 5.20 17.91 ± 7.41 0.007
Testosterone (ng/ml) 0.38 ± 0.13 0.48 ± 0.16 0.009
Triglyceride (mg/dl) 78.73 ± 27.13 93.5 ± 35.24 0.04
Cholesterol (mg/dl) 155.82 ± 27014 153.11 ± 26.51 NS
HDL-C (mg/dl) 46.64 ± 8.62 41.07 ± 9.58 0.014
LDL-C (mg/dl) 92.41 ± 21.19 93.23 ± 23.45 NS
VLDL-C (mg/dl) 15.71 ± 5.42 18.7 ± 7.04 NS
FPG (mg/dl) 94.85 ± 7.77 97 ± 8.72 NS
HOMA-IR 3.05 ± 1.06 3.84 ± 1.08 0.005
HOMA-B 161.55 ± 74.69 201.32 ± 101.97 NS
BUN (mg/dl) 11.52 ± 3.37 11.64 ± 2.69 NS
Creatinine (mg/dl) 0.75 ± 0.14 0.7 ± 0.16 NS
FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, 
low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein 
cholesterol; BUN, blood urea nitrogen; HOMA-IR, homeostasis model assessments 
for insulin resistance; HOMA-B, homeostasis model assessments for B cell function 
NS, Not significant. Data is presented as mean ± SD.
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Discussion
Our data indicate that there is no significant differences in 
omentin and vaspin plasma level in PCOS with normal BMI 
compare to non-PCOS patients. Tan et al. [7] reported patients 
with PCOS l had lower omentin levels. The data of Muhed et al. 
(2009) showed a significant decrease in plasma omental adipok-
ines levels in women with PCOS compared to that of the control 
group. The differences in BMI between obese PCOS patients in 
Muhed research and nonobese patients in our study can explain 
this discrepancy [11]. According to Karshow et al. (2004) adipose 
tissue is a complex essential and highly active metabolic and 
endocrine organ. Adipose tissue expresses and secretes cytokins 
such as adiponectin, resistin, omentin etc [3].
There is a controversy between our results, where no signifi-
cant changes of vaspin plasma levels in nonobese PCOS women 
was observed and other studies which showed increased vaspin 
plasma levels in PCOS women [12,18,19]. In Cakal et al. and Tan 
et al. studies obese (BMI >27) PCOS women were presented with 
increased vaspin levels, while in Koiou et al. study both obese and 
nonobese PCOS women had elevated vaspin levels compared 
to matched controls. Increased vaspin levels in Koiou et al. [18] 
study might represent a compensatory mechanism to preserve 
insulin sensitivity and glucose tolerance which are impaired in 
obesity.
Our findings indicate a significant increase in HOMA-IR 
(insulin resistance) in PCOS subjects although our data didn’t 
show any significant differences in FPG in the PCOS group. It 
can be concluded that as long as hyperinsulinemia is overcome 
by insulin resistance, glucose levels remain normal. We hypoth-
esize that the high level of insulin in nonobese PCOS patients is 
responsible for the hyperanderogenism. It is possible that hyper-
insulinemia as a result of insulin resistance causes the  Luteinizing 
hormone (LH) effect on ovarian theca cells leading to androgen 
excess because the theca cells from PCOS women are intrinsically 
programmed to overproduce androgen [20]. Our data showed a 
significant higher concentration of testosterone in PCOS group as 
compared to the control group.
Studies with the euglycemic clamp technique indicate that 
insulin resistance is present in both obese and nonobese women 
with PCOS compared to normal women with the matched age 
and weight [21]. Dunaif et al. (1998) in accordance with our data 
have reported that insulin resistance is a unique and common 
finding in women with PCOS independent of obesity.
In this case control study, significant differences were seen 
between the PCOS group and the control groups in TG and 
HDL-C plasma concentration. Two novel studies in accordance 
with our findings showed a significant increase in TG and a signif-
icant decrease in HDL-c in PCOS patients [7,11]. The data from 
this small study suggest that dyslipidemia is secondary to excess 
androgen action in concert with the hyperinsulinemia associated 
with insulin resistance. Some studies had shown that treatment 
with nonsteroidal antiandrogen or insulin-sensitizing medication 
reduces circulating levels of TGs, LDL-C and the atherogenicity 
of the lipid profile in women with PCOS [22–25].
Conclusion
If hyperanderogenism and insulin resistance are early warning 
signs of increasing risk of PCOS, these patients are prime candi-
dates for preventive medicine. It is important that primary 
care providers begin to recognize these androgen and insulin 
parameters as a clue to screening of a complex, lifelong pattern, 
potentially placing women at risk for PCOS but adipokines 
changes, including vaspin and omentin are consequences of fat 
cell accumulation but not PCOS in obese PCOS.
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